Abstract
Neuroinflammation plays pivotal roles in the pathogenesis of Alzheimer’s disease (AD). IL-6 is pleiotropic cytokine which plays significant pathological role in inflammatory diseases and causes prolonged inflammation. Additionally, IL-6 activates microglia cells and enhances the accumulation of amyloid-β peptides. Moreover, IL-6 signal transduction is mediated by membrane-bound and soluble IL-6 receptors. Tocilizumab which is a humanized anti-human IL-6 receptor (IL-6R) monoclonal antibody binds to both of these receptors and inhibits IL-6 signaling by this route. The objective was to investigate tocilizumab’s potential effects in the treatment of AD. Male Sprague–Dawley rats were divided into three groups: sham (control), streptozotocin (STZ), and tocilizumab-STZ. We used a single dose of intracerebroventricular (ICV) tocilizumab, beginning 1 h prior to injection of STZ for 3 weeks. The rats in STZ and tocilizumab-STZ groups were given ICV-STZ (3 mg/kg). Behavioral parameters were evaluated on days 17–20 and the rats were sacrificed on day-21 to examine histopathological changes. STZ injection caused significant decrease in the mean escape latency in passive avoidance and also declined the performance improvement in Morris water maze tests. Tocilizumab-STZ group significantly improved learning and spatial memory functions by increasing RLT in the passive avoidance and by shortening escape latency in reaching the platform in the Morris water maze. Histopathological changes were examined using hematoxylin and eosin and immunohistochemical (IHC) stainings. IHC analysis revealed that while protein expressions of amyloid-ß (3.5 ± 0.2) and IL-6 (2.9 ± 0.4) showed intense immune-positivity in STZ group, amyloid-ß (1.3 ± 0.1) and IL-6 (1.5 ± 0.2) immunoreactivities were substantially decreased in tocilizumab treatment group. We conclude that tocilizumab treatment attenuated significantly STZ-induced cognitive impairment and histopathological changes. Further studies would be desirable to investigate clinically relevant protective effects of tocilizumab in AD.
Similar content being viewed by others
References
Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW (2011) Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res 1368:239–247
Isik AT, Çelik T, Ulusoy G et al (2009) Curcumin ameliorates impaired insulin/IGF signaling and memory deficit in a streptozotocin-treated rat model. AGE 31:39–49
Weiss EM, Kohler CG, Vonbank J, Stadelmann E, Kemmler G, Hinterhuber H (2008) Impairment in emotion recognition abilities in patients with mild cognitive impairment, early and moderate Alzheimer’s disease compared with healthy comparison subjects. Am J Geriatr Psychiatry 16:974–980
Heneka MT, O’Banion MK, Terwel D, Kummer MP (2010) Neuroinflammatory processes in Alzheimer’s disease. J Neural Transm 117:919–947
Zhang YY, Fan YC, Wang M, Wang D, Li XH (2013) Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer’s disease. Clin Interv Aging 8:103–110
Tanaka T, Narazaki M, Kishimoto T (2012) Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 52:199–219
Tanaka T, Narazaki M, Ogata A, Kishimoto T (2014) A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol 26:88–96
Guptarak J, Wanchoo S, Durham-Lee J, Wu Y, Zivadinovic D, Paulucci-Holthauzen A (2013) Inhibition of IL-6 signaling: a novel therapeutic approach to treating spinal cord injury pain. Pain 154:1115–1128
Fridman JS, Scherle PA, Collins R et al (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184:5298–5307
Wu GI, Chai N, Kim I, Klein AS, Jordan SC (2013) Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization. Transpl Immunol 28:138–143
Mayer G, Nitsch R, Hoyer S (1990) Effects of changes in peripheral and cerebral glucose metabolism on locomotor activity, learning and memory in adult male rats. Brain Res 532:91–100
Blokland A, Jolles J (2014) Spatial learning deficit and reduced hippocampal ChAT activity in rats after an i.c.v. injection of streptozotocin. Pharmacol Biochem Behav 44:491–494
Rodrigues L, Dutra MF, Ilha J, Biasibetti R, Quincozes-Santos A, Leite MC (2010) Treadmill training restores spatial cognitive deficits and neurochemical alterations in the hippocampus of rats submitted to an intracerebroventricular administration of streptozotocin. J Neural Transm 117:1295–1305
Chu S, Gu J, Feng L, Liu J, Zhang M, Jia X (2014) Ginsenoside Rg5 improves cognitive dysfunction and beta-amyloid deposition in STZ-induced memory impaired rats via attenuating neuroinflammatory responses. Int Immunopharmacol 19:317–326
Sharma M, Gupta YK (2001) Effect of chronic treatment of melatonin on learning, memory and oxidative deficiencies induced by intracerebroventricular streptozotocin in rats. Pharmacol Biochem Behav 70:325–331
Saxena G, Bharti S, Kamat PK, Sharma S, Nath C (2010) Melatonin alleviates memory deficits and neuronal degeneration induced by intracerebroventricular administration of streptozotocin in rats. Pharmacol Biochem Behav 94:397–403
Nakahara N, Iga Y, Mizobe F, Kawanishi G (1998) Effects of intracerebroventricular injection of AF64A on learning behaviors in rats. Jpn J Pharmacol 48:121–130
Elcioglu HK, Kabasakal L, Alan S, Şalva E, Tufan T, Karan MA (2013) Thalidomide attenuates learning and memory deficits induced by intracerebroventricular administration of streptozotocin in rats. Biotech Histochem 88:145–152
Morris R (1984) Development of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47–60
Provias J, Jeynes B (2010) Immunohistochemical detection of receptor-associated protein in normal human brain and Alzheimer’s disease. Pathol Res Int 2010:173496. doi:10.4061/2010/173496
Ogata A, Hirano T, Hishitani Y, Tanaka T (2012) Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 5:27–42
Kaly L, Rosner I (2012) Tocilizumab-a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol 26:157–165
Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX (2009) Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer’s disease. Am J Pathol 175:2089–2098
Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101:757–770
Ejaz Ahmed M, Khan MM, Javed H et al (2013) Amelioration of cognitive impairment and neurodegeneration by catechin hydrate in rat model of streptozotocin-induced experimental dementia of Alzheimer’s type. Neurochem Int 62:492–501
Gutierres JM, Carvalho FB, Schetinger MR, Marisco P, Agostinho P, Rodrigues M (2014) Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-induced sporadic dementia of Alzheimer’s type. Life Sci 96:7–17
Massoud F, Gauthier S (2010) Update on the pharmacological treatment of Alzheimer’s disease. Curr Neuropharmacol 8:69–80
Rajasekar N, Dwivedi S, Tota SK et al (2013) Neuroprotective effect of curcumin on okadaic acid induced memory impairment in mice. Eur J Pharmacol 715:381–394
Bın Z, Zhı-Gang W, Jıe D, Nıng L, Da-Mıng W, Lıang-Caı D (2014) Chronic lipopolysaccharide exposure induces cognitive dysfunction without affecting BDNF expression in the rat hippocampus. Exp Ther Med 7:750–754
Reale M, Iarlori C, Gambi F et al (2004) Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol 148:162–171
Elcioglu HK, Kabasakal L, Tufan F et al (2015) Effects of systemic thalidomide and intracerebroventricular etanercept and infliximab in a streptozotocin-induced dementia model in rats. Acta Histochem 117:176–181
Hartman J, Frishman WH (2014) Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev 22:147–151
Atzeni F, Ventura D, Batticciotto A, Boccassini L, Sarzi-Puttini P (2012) Interleukin 6 blockade: tocilizumab in psoriatic arthritis. J Rheumatol 89(Suppl):97–99
Mizwicki MT, Fiala M, Magpantay L et al (2012) Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis 1:305–315
Yokota S, Tanaka T, Kishimoto T (2012) Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis 4:387–397
Fabiola A, Benucci M, Salli S, Bongiovanni S, Boccassini L, Sarzi-Puttini P (2013) Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev 12:575–579
Dolatabadi HRD, Reisi P, Alaei H, Malekabadi HA, Pilehvarian AA (2012) Folic acid and coenzyme Q10 ameliorate cognitive dysfunction in the rats with intracerebroventricular injection of streptozotocin. Iranian J Basic Med Sci 15:719–724
Hsu LJ, Mallory M, Xia Y et al (1998) Expression pattern of synucleins (non-A beta component of Alzheimer’s disease amyloid precursor protein/alpha-synuclein) during murine brain development. J Neurochem 71:338–344
Nguven JT, Yamani A, Kiso Y (2006) Views on amyloid hypothesis and secretase inhibitors for treating Alzheimer’s disease: progress and problems. Curr Pharm Res 12:4295–4312
Acknowledgments
This research work was supported by the Marmara University Scientific Research Community (Project No: SAG-C-YLP-120613-0241).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
None of the authors have any potential financial or commercial conflict of interest associated with this research manuscript.
Rights and permissions
About this article
Cite this article
Elcioğlu, H.K., Aslan, E., Ahmad, S. et al. Tocilizumab’s effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer’s model. Mol Cell Biochem 420, 21–28 (2016). https://doi.org/10.1007/s11010-016-2762-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-016-2762-6